Evidence map›Paper›PMID 30679414›Full record

Trial reportAnnals of transplantation2019

Good Results with Individually Adapted Long-Term Immunosuppression Following Alemtuzumab Versus ATG Induction Therapy in Combined Kidney-Pancreas Transplantation: A Single-Center Report.

Claudia Bösmüller, Franka Messner, Christian Margreiter, Robert Öllinger, Manuel Maglione, Rupert Oberhuber, Stefan Scheidl, Hannes Neuwirt, Dietmar Öfner, Raimund Margreiter and 1 more

Open access · hybridAbstract readLetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Claudia BösmüllerDepartment of Transplant Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Franka MessnerDepartment of Transplant Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Christian MargreiterDepartment of Transplant Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Robert ÖllingerDepartment of General Surgery, Charité Virchow Hospital Berlin, Berlin, Germany.
Manuel MaglioneDepartment of Transplant Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Rupert OberhuberDepartment of Transplant Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Stefan ScheidlDepartment of Transplant Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Hannes NeuwirtDepartment of Internal Medicine IV (Nephrology and Hypertension), Medical University of Innsbruck, Innsbruck, Austria.
Dietmar ÖfnerDepartment of Transplant Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Raimund MargreiterDepartment of Transplant Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Stefan SchneebergerDepartment of Transplant Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Universität Innsbruck · ATInnsbruck Medical University · ATCharité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunosuppression TherapyAdultAlemtuzumabAntilymphocyte SerumDiabetes Mellitus, Type 1FemaleGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsKidney TransplantationMaleMiddle AgedPancreas TransplantationSurvival RateTreatment OutcomeAlemtuzumabAntilymphocyte SerumImmunosuppressive Agents

Identifiers

PMID30679414
PMCPMC6363467
OpenAlexW2912472754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.